

Summary of the December 2014 Gavi Alliance Board Meeting

In December 2015, the GAVI Alliance Board made a number of decisions and recommendations summarised below:

Ebola - the Gavi Board endorsed a commitment of up to US\$300M for procurement of Ebola vaccines pending WHO recommendations. In addition up to US\$90M to support countries introduce the new vaccines and rebuild the health system. The release of funds will be done under the oversight of the Executive Committee (EC) following the WHO recommendations. The Board noted that to meet the funding requirements of the Ebola Envelope, Gavi could use a combination of existing and new sources of funds and join forces with initiatives which have already pledged funding to address the Ebola crisis.

In light of the rapidly evolving nature of Ebola vaccine development, the Board resolved that there be a special convening of the EC by teleconference in January 2015 and February 2015 and an update to the Board at their retreat in March 2015. The Board could then review the status and progress, especially any new data regarding clinical trials, efficacy, and other strategic issues, and discuss any needed adjustments or decisions regarding the way forward .

The Board also noted its support for funding a potential stockpile for second generation Ebola vaccines, designed according to WHO-convened guidance, and related maintenance and operational costs, and requested the Secretariat to explore the associated financial implications.

Replenishment - a number of donors confirmed their commitments to Gavi in advance of the Berlin conference amounting to about 55% of the total ask of US\$7.5 bn. There seems to be a lot of optimism in mobilizing resources close to the target. Major commitments for 2016-2020 to date include EUR 500 M from Germany, CAD 500M of Canada, US1Bn from the UK and the IFFim bond which raised US\$500M. A number of new donors have indicated commitments to pledge in Berlin including Saudi Arabia, Qatar and UAE. The dialogue with China continues, on engaging more Chinese vaccine manufacturers as well as Gavi's potential influence over China's domestic EPI policy. Additional and separate announcements are expected on Ebola including from the ADB.

Governance - the Board confirmed the nomination of Dr Flavia Bustreo, WHO's Assistant Director General for Family, Women's and Children's Health as Vice Chair of the Board, Chair of the Governance Committee and Vice Chair for the Executive committee for the term of 1 January 2015 to 31 December 2016.

Risk Management - a new policy for risk management was endorsed strengthening request by donors for Gavi to differentiate fiduciary risk from programmatic risk.

Business Plan 2015 - the Gavi Board approved US\$250M for supporting the Secretariat and implementing partners to the Gavi business plan. Furthermore, discussions were initiated for changing the current operating model to support the implementation of the 2016-2020 approved strategy to one that is more country focused.

Finally to note the Board discussed the GVAP progress report with interest in re engaging in a joint dialogue on the lagging goals and with the most critical countries and key immunization partners.